Plasma ceramides are altered in mild cognitive impairment and predict cognitive decline and hippocampal volume loss

A blood-based biomarker of Alzheimer's disease (AD) would be superior to cerebrospinal fluid (CSF) and neuroimaging measures in terms of cost, invasiveness, and feasibility for repeated measures. We previously reported that blood ceramides varied in relation to timing of memory impairment in a...

Full description

Saved in:

Bibliographic Details
Published in:	Alzheimer's & dementia Vol. 6; no. 5; p. 378
Main Authors:	Mielke, Michelle M, Haughey, Norman J, Bandaru, Veera Venkata Ratnam, Schech, Steven, Carrick, Richard, Carlson, Michelle C, Mori, Susumu, Miller, Michael I, Ceritoglu, Can, Brown, Timothy, Albert, Marilyn, Lyketsos, Constantine G
Format:	Journal Article
Language:	English
Published:	United States 01.09.2010
Subjects:	Aged Aged, 80 and over Alzheimer Disease - blood Analysis of Variance Ceramides - blood Ceramides - classification Cognition Disorders - blood Cognition Disorders - pathology Female Functional Laterality Hippocampus - pathology Humans Linear Models Magnetic Resonance Imaging - methods Male Neuropsychological Tests Predictive Value of Tests Psychiatric Status Rating Scales
ISSN:	1552-5279, 1552-5279
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!